Physician profile
Suzanne E Anders
NPI 1750773958
$4,812.27
in general payments reported to CMS, 2019-2025
15 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $411 · 2023: $783 · 2024: $2,750 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746 · Travel and Lodging: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.61 |
| Travel and Lodging | $1,223.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,644.29 | 2021-2025 | |
| Abbott Laboratories | $1,590.74 | 2023-2024 | Cardiomems |
| Astrazeneca Pharmaceuticals Lp | $550.14 | 2021-2025 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $274.72 | 2023-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $142.33 | 2023-2024 | Xarelto |
| Bridgebio Pharma, INC. | $108.51 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $92.20 | 2022-2024 | |
| Pfizer INC. | $86.29 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $73.54 | 2024-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.03 | 2023-2024 | Jardiance |
| Amgen INC. | $62.00 | 2024 | Repatha |
| Novo Nordisk INC | $43.35 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $34.72 | 2023-2024 | Watchman Flx |
| Baxter Healthcare | $21.61 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $20.80 | 2024 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.